2023 World Conference on Lung Cancer (Posters)-P2.31. Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy

P2.31. Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy - PDF(Abstract)

Back to course

Pdf Summary

This document is the summary of a presentation at the WCLC 2023 conference in the session on Global Health, Health Services, and Health Economics. The presentation focused on the real-world treatment patterns and outcomes in patients with advanced non-small cell lung cancer (aNSCLC) who were treated after prior chemotherapy and immunotherapy. The study aimed to fill the gaps in knowledge regarding the use of taxanes and other chemotherapy treatments in this patient population and to evaluate the clinical outcomes in a real-world setting.<br /><br />The researchers used the nationwide Flatiron Health electronic health record-derived deidentified database to select patients with aNSCLC who initiated treatment between January 2019 and June 2021. The treatment patterns and clinical outcomes, including overall survival (OS), time to treatment discontinuation (TTD), and time to next treatment (TTNT), were analyzed. The patients were grouped based on the type of treatment they received, such as taxane monotherapy, taxane combination therapy, non-taxane monotherapy, and others.<br /><br />The results showed that out of the 1216 eligible patients in the real-world cohort, the majority had non-squamous histology and a small percentage had driver mutations. Most patients received taxane combination therapy as their index treatment, followed by taxane monotherapy and non-taxane monotherapy. The use of taxane combination therapy decreased in later lines of therapy. Non-taxane monotherapy was the most common therapy used after taxane-based index treatment.<br /><br />The study found that the prognosis for patients with aNSCLC treated after prior platinum chemotherapy and immunotherapy was poor, with 50% of patients not receiving subsequent treatment due to death on index treatment. The median overall survival was similar across taxane combination therapy and monotherapy categories, emphasizing the need for new treatment options in this setting.<br /><br />In conclusion, this real-world study highlights the limited treatment options and poor prognosis for patients with aNSCLC who have received prior platinum chemotherapy and immunotherapy. The findings emphasize the need for new treatment strategies to improve outcomes in this patient population.

Asset Subtitle

Shivani Mhatre

Meta Tag

Speaker Shivani Mhatre

Topic Global Health, Health Services & Health Economics: Real World Data

Keywords

WCLC 2023

Global Health

Health Services

Health Economics

non-small cell lung cancer

advanced NSCLC

chemotherapy

immunotherapy

taxanes

clinical outcomes